AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) The use of a compound of general formula (I):



(I)

wherein X+ is selected from the group consisting of N+(R_1, R_2, R_3) and P+(R_1, R_2, R_3), wherein R_1, R_2 and R_3, which are the same or different, are selected from the group consisting of hydrogen and C_1-C_9 straight or branched alkyl groups,

-CH=NH(NH_2), -NH_2, -OH; or two or more R_1, R_2 and R_3, together with the nitrogen atom which they are linked to, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic system; with the proviso that at least one of R_1, R_2 and R_3 is different from hydrogen;

Z is selected from

OR_4,

-$OCOOR_4$,

-$OCONHR_4$,

-$OCSNHR_4$,

-$OCSOR_4$

-NHR_4,

$-NHCOR_4$,

$-NHCSR_4$,

$-NHCOOR_4$,

$-NHCSOR_4$,

$-NHCONHR_4$,

$-NHCSNHR_4$,

$-NHSOR_4$,

$-NHSONHR_4$,

$-NHSO_2R_4$,

$-NHSO_2NHR_4$,

$-SR_4$,

wherein R_4 is a C_2-C_{20} saturated or unsaturated, straight or branched alkyl group;

Y- is selected from the group consisting of -COO-, PO_3H, -OPO3H-, tetrazolate-5-yl;

salts, enantiomers and racemic mixtures thereof, for the preparation of an antitumor medicament.

2. (original) The use according to claim 1 of a compound of formula (I), wherein, independently of one another,

- X is trimethylammonium or a group $N+(R_1, R_2, R_3)$ wherein two or more R_1, R_2 and R_3, together with the nitrogen atom which they are linked to,

form a heterocyclic system, which is selected from morpholinium, pyridinium, pyrrolidinium, quinolinium and quinuclidinium;

- R_4 is selected from heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and eicosyl;
- Z is a ureido (-$NHCONHR_4$) or carbamate (-$NHCOOR_4$, -$OCONHR_4$) group.

3. (original) The use according to claim 2 of a compound which is selected from the group consisting of

- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate;
- R,S-4-quinuclidinium-3-(tetradecyloxycarbonyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-oxybutyric acid chloride;
- R,S-4-trimethylphosphonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(octyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-octyloxybutyrate;
- R,S-4-trimethylammonium-3-tetradecyloxybutyrate;
- R,S-1-guanidinium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;
- R,S-1-trimethylammonium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;
- R,S-3-quinuclidinium-2-(tetradecyloxcarbonyl)-oxy-1-propanephosphonate monobasic;

- R,S-3-trimethylammonium-2-(nonylaminocarbonyl)-oxy-1-propanephosphonate monobasic;
- R,S-3-pyridinium-2-(nonylaminocarbonyl)-oxy-1-propanephosphonic acid chloride;
- R-4-trimethylammonium-3-(tetradecylcarbomoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(undecylcarbamoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(heptylcarbamoyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-(nonylthiocarbamoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(noncarbamoyl)-aminobutyrate;
- S-4-trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate;
- S-4-trimethylammonium-3-(tetradecylcarbamyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-tetradecylaminobutyrate;
- R,S-4-trimethylammonium-3-octylaminobutyrate;
- R,S-4-trimethylammonium-3-(decansulfonyl)aminobutyrate;
- R,S-4-trimethylammonium-3-(nonylsulfamoyl)aminobutyrate;
- S-4-trimethylammonium-3-(dodecansulfonyl)aminobutyrate;
- R-4-trimethylammonium-3-(dodecansulfonyl) aminobutyrate;
- S-4-trimethylammonium-3-(undecylsulfamoyl)aminobutyrate;
- R-4-trimethylammonium-3-(undecylsulfamoyl)aminobutyrate;
- R-4-trimethylammonium-3-(dodecylcarbamoyl) aminobutyrate;
- R-4-trimethylammonium-3-(10-phenoxydecylcarbamoyl)aminobutyrate;
- R-4-trimethylammonium-3-(trans-b-styrenesulfonyl)aminobutyrate

4. (original) The use according to claim 3, of the compound R-4-trimethylammonium-3-(tetradecylcarbamoyl)-aminobutyrate.

5. (currently amended) The use of a compound (I) according to ~~claims 1-4~~ claim 1 for the preparation of an antitumor medicament for the treatment of leukaemias and hepatocarcinomas.

6. (currently amended) A therapeutic preparation containing a compound according to ~~anyone of claims 1-4~~ claim 1 in combination with an antitumor agent selected from cytotoxic or cytostatic compounds, antimetabolites, hormone antagonists, alcaloids, antibiotics, in particular antracyclines, alkylating agents, peptides, agents modifying the biological response, cytokines, for simultaneous separate or sequential administration to a tumor patient.

7. (original) A preparation according to claim 6, containing a combination of a compound according to anyone of claims 1-4 and an antracycline.

8. (original) A preparation according to claim 7, wherein the antracycline is doxorubicin.